Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.67 |
| ▸ | TYMP | P19971 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PYGM | P11217 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62321 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL7182936 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL20875706 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL22992480 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL62322 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL22992424 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL29509957 | 0.99 | TK2 (0.66) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL14429106 | 0.95 | TK2 (0.62) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL15691446 | 0.91 | TK2 (0.58) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL15691496 | 0.91 | TK2 (0.58) | TK2TYMPALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586184-B2 | Rearranging target nucleotide sequences; obtain cells, transfor with nucleotide sequences, detecting nucleotide sequences adjustment in prokaryotic cell | VALIGEN (U.S.), INC. | 2003-07-01 | — | — | US | claimed |
| US-20020151072-A1 | Chimeric mutational vectors | VALIGEN (U.S), INC. | 2002-10-17 | — | — | US | claimed |
| EP-1078097-A4 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | KIMERAGEN INC (US) | 2002-06-05 | — | — | EP | claimed |
| EP-1084272-A4 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | KIMERAGEN INC (US) | 2002-03-13 | — | — | EP | claimed |
| US-6211351-B1 | FOR INTRODUCTION OF GENETIC CHANGES IN EUKARYOTIC CELLS | VALIGEN (US), INC. | 2001-04-03 | — | — | US | claimed |
| EP-1084272-A1 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | Kimeragen Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1078097-A1 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | Kimeragen Inc. (US) | 2001-02-28 | — | — | EP | claimed |
| US-6010907-A | TRANSFORMING TARGET DNA SEQUENCES | KIMERAGEN, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-6004804-A | 3'-EXONUCLEASE PROTECTED DUPLEX MUTATIONAL VECTORS; USED TO MAKE SPECIFIC GENETIC ALTERATIONS IN THE GENOME AND IN PLASMIDS OF TARGET PROKARYOTIC CELLS | KIMERAGEN, INC. (US) | 1999-12-21 | — | — | US | claimed |
| WO-1999058702-A1 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | KIMERAGEN, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999058723-A1 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | KIMERAGEN, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | BEIJING RIBIO PHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| EP-1242633-B1 | NUCLEIC ACID AMPLIFICATION AND DETECTION OF MYCOBACTERIUM SPECIES | GEN PROBE INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-0741741-B1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 2002-08-28 | — | — | EP | disclosed |
| US-6066447-A | INCLUDING NUCLEOSIDE DIMERS WITH MODIFIED BACKBONES; FOR VIRICIDES AND ANTISENSE AGENTS | NOVARTIS CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | UMPS, TYMP, DPYD | TK2 126/4885TYMP 2/4885ALDH1A1 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.